Newcells Biotech is pleased to announce that it has appointed Dr Frank Armstrong to its Board as a Non-executive Director. “Attracting an executive of Frank’s proven track-record and expertise is another significant
Newcells Biotech are one of three Phase I contract winners of a challenge-led competition that funds collaborations between industry, academics and SMEs to solve business and scientific ‘Challenges’. The NC3Rs challenge (named ImmuLiver), sponsored by Sanofi
Newcells Biotech has announced that Dr Colin Brown, one of the world’s leading experts on drug transport and drug toxicity in kidney will join the company as Director of ADMET Technology. The company has also
Newcells Biotech has secured a £2 million investment from NVM Private Equity and Northstar Ventures to support its ambitious growth plans.
As the NHS marks its 70th birthday, the BBC explores the genetic advances changing the face of medicine, including the extraordinary science that helped a blind man to see again.
This year’s British Toxicology Society Congress 2018 saw the IVTS Poster Prize awarded to our own Dr Valeria Chichagova, for her work in human retina models.
Newcells Biotech in partnership with Newcastle University has been awarded further funding from the NC3R CRACK IT project to create 3D retinal organoids that more closely recapitulate the structure and function of the human retina.
Led by Dr Colin Brown, Newcells Biotech has licensed-in an in vitro ADMET assay platform from Newcastle University to determine how new drugs are transported by the kidney.
Newcells Biotech has joined the StemBANCC project, a pan-EU consortium made up of major pharmaceutical and academe groups.
Newcells Biotech have been awarded a grant to employ a PhD student to help develop models of the human lung from iPSCs.
Newcells Biotech has been successful in partnering with Newcastle University to receive funding in a £100K phase I NC3R CRACK IT project to develop a new skin metabolism model using iPSC derived skin cells.
Newcells Biotech Ltd has signed a patent license agreement with ID Pharma Co., Ltd to license and commercialise ID Pharma Co., Ltd patented technologies in the Sendai virus vectors for reprogramming cells to induced pluripotent stem cells (iPSCs).